[Antiarrhythmic drug therapy in patients with heart failure].
Nakamura
Kazufumi
K
Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Nishii
Nobuhiro
N
Ohe
Tohru
T
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000638:Amiodarone / Q000627:therapeutic use; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D016757:Death, Sudden, Cardiac / Q000209:etiology / Q000517:prevention & control; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006352:Heart Ventricles; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000451:Mineralocorticoid Receptor Antagonists; D000638:Amiodarone